ORKA vs OWL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ORKA · Oruka Therapeutics$102.86 ▲ 7.12%
OWL · Blue Owl Capital$9.82 ▼ 0.71%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ORKA +267.9%
- OWL -29.9%
Head to head
| Metric | ORKA | OWL |
|---|---|---|
| Price | $102.86 | $9.82 |
| Change today | ▲ 7.12% | ▼ 0.71% |
| Market cap | $6.81B | $6.80B |
| Return, 3 months | -2.2% | -14.1% |
| Return, year to date | +239.4% | -30.1% |
| Return, 1 year | +270.7% | -31.3% |
| P/E (TTM) | – | 70.1 |
| P/B | 6.1 | 3.5 |
| P/E percentile vs own 5y | 17th | 31st |
| Dividend yield | – | 9.27% |
| Revenue growth (YoY, latest qtr) | – | +7.1% |
| Net profit growth (YoY) | -67.7% | -14.2% |
| Gross margin | – | 53.5% |
| Operating margin | – | 16.9% |
| Net margin | – | 2.7% |
| Return on equity | -18.3% | 3.7% |
| Analyst target vs. price | +46.3% | +25.2% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 67 | 50 |
| 30-day volatility | 61.7% | 48.3% |
| Max drawdown, 1 year | -36.4% | -49.7% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ORKA is the largest of the group by market value.
- ORKA has returned the most over the past year.
- OWL has been the calmest stock over the last 30 days.